Citigroup’s Summit Therapeutics SMMT Stock Holding History

Citigroup’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-57,500	Closed	-$1.11M	–	5889
2025 Q1	$1.11M	Buy	+57,500	New	+$1.15M	﹤0.01%	3178

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Citigroup's SMMT Position: Q2 2026 in Review

Citigroup increased its Summit Therapeutics (SMMT) stake by 259% in Q2 2026, buying an estimated $9.13M and bringing the position to 714,000 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1590.

Citigroup first reported a position in SMMT in Q2 2015 and has held it in 37 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Citigroup held 714,000 shares of Summit Therapeutics worth $10.4M as of Q2 2026.
Citigroup bought 514,867 Summit Therapeutics shares in Q2 2026, an estimated $9.13M.
Summit Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1590 holding.
Citigroup first reported a position in Summit Therapeutics in Q2 2015 and has held it in 37 quarters since.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.